B Cell News and Research

RSS

Scientists apply fuzzy logic modeling to predict aging progresses in cells, organisms

The process of aging disturbs a broad range of cellular mechanisms in a complex fashion and is not well understood. Computer models using fuzzy logic might help to unravel these complexities and predict how aging progresses in cells and organisms, according to a study from Drexel University in Philadelphia and Children's Hospital Boston.

23 Jun 2010

Phase I/II clinical trials show crizotinib reduces lung cancer tumors

Patients with a specific kind of lung cancer may benefit from a Phase III clinical trial offered by the Moores UCSD Cancer Center. The new drug, crizotinib, under development by Pfizer, showed dramatic results in reducing lung cancer tumors in some patients during Phase I and II clinical trials.

23 Jun 2010

Mice treated with XOMA 052 experiences improvement in measures associated with diabetes: Endocrinology

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced the publication of data from a mouse model of diet-induced obesity in the June, 2010 edition of the journal Endocrinology. The data showed that mice treated with XOMA 052 both prophylactically and therapeutically experienced improvement in measures associated with diabetes and cardiovascular disease including reduction in glycosylated hemoglobin levels, improvement in glucose control, improved beta-cell survival and function, and a reduction in total cholesterol without reduction in high density lipoprotein.

23 Jun 2010

Cell>Point submits IND application for Phase 1b/2 99mTc-EC-G diagnostic trial in assessing CAD patients

Cell>Point announced today that it has submitted to the Food and Drug Administration an Investigational New Drug (IND) application for a Phase 1b/2 trial of its 99mTc-EC-G diagnostic in assessing patients with Coronary Artery Disease (CAD).

23 Jun 2010

FDA grants Tolera's TOL101 orphan drug designation for treatment of T1DM

Tolera Therapeutics, Inc., was granted orphan drug status by the United States Food and Drug Administration (FDA) for TOL101 (anti-TCR murine monoclonal antibody, type IgM), for treatment of recent onset immune-mediated Type 1 diabetes mellitus (T1DM). Designation is granted for treatment of patients sixteen years of age and younger with immune-mediated T1DM and preserved pancreatic beta-cell function, commonly referred to as juvenile diabetes.

23 Jun 2010

World's first invisible-in-the-canal hearing aid launched

Starkey Laboratories, Inc., one of the world's leading hearing technology companies, is excited to introduce the S Series™ iQ OtoLens™, the world's first invisible-in-the-canal (IIC) hearing aid. OtoLens, a custom-molded hearing aid built using Starkey's Comfort Fit process, lives in the second bend of the ear, meaning that it is truly 100 percent invisible.

22 Jun 2010

Fructose makes cells mature into fat cells in belly fat, study finds

Fructose, the sugar widely used as high-fructose corn syrup in soft drinks and processed foods, often gets some of the blame for the widespread rise in obesity. Now a laboratory study has found that when fructose is present as children's fat cells mature, it makes more of these cells mature into fat cells in belly fat and less able to respond to insulin in both belly fat and fat located below the skin.

22 Jun 2010

CCBC fourth-quarter fiscal 2010 net revenues up 24.6%

China Cord Blood Corporation, China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced preliminary unaudited financial results for the fourth quarter and full year fiscal 2010.

22 Jun 2010

Biovest targets mantle cell lymphoma as next indication for BiovaxID

Biovest International, Inc. (Other OTC:BVTI) today announced at the Active Immunotherapeutics Forum in Barcelona, Spain, that the Company is targeting mantle cell lymphoma, in addition to follicular lymphoma, as a next indication for its personalized cancer vaccine, BiovaxID. At the conference, the Company reviewed positive data from an open label Phase II mantle cell lymphoma clinical trial and reported plans to meet with the FDA later this year to discuss a pathway to seek regulatory approval for this hematological indication for which there is no current consensus standard-of-care.

22 Jun 2010

New legal, ethical framework needs to be placed around banking of human biological material: Review

A lawyer and researcher at the Johns Hopkins Berman Institute of Bioethics says a new legal and ethical framework needs to be placed around the donation and banking of human biological material, one that would more clearly define the terms of the material's use - and address donor expectations before research begins.

22 Jun 2010

SynCon DNA vaccine shows advantages in magnitude and breadth of immune responses in non-human primates

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the peer-reviewed journal Molecular Therapy has published a paper entitled "Comparative Analysis of Immune Responses Induced by Vaccination With SIV Antigens by Recombinant Ad5 Vector or Plasmid DNA in Rhesus Macaques." The paper, co-authored by researchers from Merck, University of Pennsylvania School of Medicine, and Inovio Pharmaceuticals, notes that significant advances in the design, formulation, and delivery of DNA plasmid-based vaccines have dramatically increased their ability to induce antigen-specific immune responses.

22 Jun 2010

Studying cells in 3-D could help develop drugs to prevent cancer from spreading: Researchers

Showing movies in 3-D has produced a box-office bonanza in recent months. Could viewing cell behavior in three dimensions lead to important advances in cancer research? A new study led by Johns Hopkins University engineers indicates it may happen. Looking at cells in 3-D, the team members concluded, yields more accurate information that could help develop drugs to prevent cancer's spread.

22 Jun 2010

Study: Complex make-up of cells could lead to new types of medicines

A surprising discovery about the complex make-up of our cells could lead to the development of new types of medicines, a study suggests. Scientists studying interactions between cell proteins - which enable the cells in our bodies to function - have shown that proteins communicate not by a series of simple one-to-one communications, but by a complex network of chemical messages.

22 Jun 2010

Chocolate bar with resveratrol may help improve memory, learning skills

Wondering where you put the car keys? Can't remember what day of the week it is? Perhaps you need to eat a new kind of chocolate bar.

22 Jun 2010

Elevation of Smurf1 may play a role in molecular basis of PAH: Study

Pulmonary arterial hypertension (PAH) is a progressive disease, marked by shortness of breath and fatigue which can be fatal if untreated. Increased pressure in the pulmonary artery and its branches is associated with dysfunctional growth control of endothelial and smooth muscle cells leading to excessive thickening of the blood vessel wall, obliteration of the lumen and right heart failure.

22 Jun 2010

OMJPI, Diamyd Medical sign agreement to develop and commercialize GAD65 antigen-based therapy

Ortho-McNeil-Janssen Pharmaceuticals, Inc. announced today it has signed an exclusive agreement with Diamyd Medical AB, a Swedish publicly traded company focusing on the development of pharmaceuticals for the treatment of autoimmune diabetes and its complications, to develop and commercialize their GAD65 antigen-based therapy for the treatment and prevention of type 1 diabetes and associated conditions.

22 Jun 2010

Diamyd Medical, Ortho-McNeil-Janssen Pharmaceuticals sign agreement for diabetes therapy

Diamyd Medical AB has signed an agreement with Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI), a Johnson & Johnson company, to develop and commercialize the Diamyd® diabetes therapy.

22 Jun 2010

Semafore's SF1126 peptidic prodrug demonstrates clinical activity in chronic lymphocytic leukemia

Semafore Pharmaceuticals today announced the presentation of preliminary clinical data demonstrating that SF1126 has clinical activity in chronic lymphocytic leukemia (CLL). SF1126 is a novel peptidic prodrug that converts to LY294002, one of the most widely studied small molecule inhibitors of both phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR). The results were presented at Cambridge Healthtech Institute's 8th Annual Next-Gen Kinase Inhibitors Oncology & Beyond Conference being held June 21-23, 2010, in Cambridge, Massachusetts.

22 Jun 2010

Discoveries in study and manipulation of human ES cells win first prize in research competition

World-recognized discoveries in the study and manipulation of human embryonic stem cells have won first prize in a prestigious applied research competition for a Hebrew University of Jerusalem researcher.

22 Jun 2010

NHLBI funds nine research grants to determine safety and efficacy of red blood cell transfusions

The National Heart, Lung, and Blood Institute, part of the National Institutes of Health, is funding nine research grants to determine if the safety and efficacy of red blood cell transfusions vary depending on how long the cells have been stored. One of the grants supports the first large, multi-center, randomized clinical trial to compare outcomes in heart surgery patients who receive transfusions of red blood cells that have been stored for shorter or longer amounts of time.

22 Jun 2010

B Cell News and Research

Scientists apply fuzzy logic modeling to predict aging progresses in cells, organisms

Phase I/II clinical trials show crizotinib reduces lung cancer tumors

Mice treated with XOMA 052 experiences improvement in measures associated with diabetes: Endocrinology

Cell>Point submits IND application for Phase 1b/2 99mTc-EC-G diagnostic trial in assessing CAD patients

FDA grants Tolera's TOL101 orphan drug designation for treatment of T1DM

World's first invisible-in-the-canal hearing aid launched

Fructose makes cells mature into fat cells in belly fat, study finds

CCBC fourth-quarter fiscal 2010 net revenues up 24.6%

Biovest targets mantle cell lymphoma as next indication for BiovaxID

New legal, ethical framework needs to be placed around banking of human biological material: Review

SynCon DNA vaccine shows advantages in magnitude and breadth of immune responses in non-human primates

Studying cells in 3-D could help develop drugs to prevent cancer from spreading: Researchers

Study: Complex make-up of cells could lead to new types of medicines

Chocolate bar with resveratrol may help improve memory, learning skills

Elevation of Smurf1 may play a role in molecular basis of PAH: Study

OMJPI, Diamyd Medical sign agreement to develop and commercialize GAD65 antigen-based therapy

Diamyd Medical, Ortho-McNeil-Janssen Pharmaceuticals sign agreement for diabetes therapy

Semafore's SF1126 peptidic prodrug demonstrates clinical activity in chronic lymphocytic leukemia

Discoveries in study and manipulation of human ES cells win first prize in research competition

NHLBI funds nine research grants to determine safety and efficacy of red blood cell transfusions

Using single B cell screening to boost antibody discovery eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News